How to Buy Fulcrum Therapeutics Stock
Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Fulcrum Therapeutics stock last closed at $6.85, up 1.03% from the previous day, and has decreased 12.18% in one year. It has overperformed other stocks in the Biotechnology industry by 0.64 percentage points. Fulcrum Therapeutics stock is currently +195.9% from its 52-week low of $2.32, and -32.38% from its 52-week high of $10.13.
As of Jun 13, 2025, there are 53.98M FULC shares outstanding. The market cap of FULC is $369.76M. In the past 24 hours, 247,000 FULC shares were traded.
How to Buy Fulcrum Therapeutics Stock
Not sure how to invest in Fulcrum Therapeutics stock? Here's how.
- Decide where to buy Fulcrum Therapeutics stock: You need to choose a stock brokerage, but don't worry - we've sifted through dozens of online brokerages and apps to help you decide where to buy Fulcrum Therapeutics stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit funds into your investment account: Choose your payment method and add your details.
- Research Fulcrum Therapeutics stock: The Fulcrum Therapeutics ticker symbol is FULC. Is Fulcrum Therapeutics stock a good investment? Should you buy shares of FULC? How do FULC's underlying business fundamentals look? Do top analysts think Fulcrum Therapeutics is a good buy? Why has FULC's stock price moved recently? (Hint: Our stock market research website can help you decide if FULC is a good stock to buy).
- Execute your FULC trade: Decide if you will purchase FULC shares at the current market price or use a limit order to purchase FULC stock at a specific price.
- Get updates on your FULC investment: Create a watchlist to important notifications about your position in Fulcrum Therapeutics stock.
Step 1: Decide where to buy Fulcrum Therapeutics stock
You will need an online brokerage account to access the NASDAQ market and buy FULC stock.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to global markets: From Technology to Real Estate, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've chosen the best brokerage, the next step is to fill out some personal details so you can invest in FULC today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to create a new brokerage account.
- Submit your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've finished signing up on the best beginner stock app, you can securely and quickly fund your account:
Check out the tutorial below if you need help transferring money into your brokerage account.
Step 4: Research Fulcrum Therapeutics stock
Once you have decided on the best place to buy Fulcrum Therapeutics stock, it's critical to evaluate their stock prior to investing, so you truly comprehend the risk as well as the upside.
Fulcrum Therapeutics quick stats
Fulcrum Therapeutics Due Diligence Checks
WallStreetZen was created to help average investors perform more in-depth fundamental analysis in less time.
You can see all of the due diligence checks on FULC's stock page.
Is FULC stock undervalued?
Investors use many financial metrics, analyses, models, and charts to gauge FULC's intrinsic value.
Using relative valuations methods:
- FULC could be undervalued based on its P/B ratio of 1.62x, relative to Biotechnology industry P/B ratio of 4.66x
You can access additional valuation research on FULC's stock here.
FULC Financials at a glance
Passed Financial Due Diligence Checks:
- There are more short-term assets than long-term liabilities on the FULC balance sheet.
- FULC's operating cash flow of $7.81M allows it to safely service it's debt of $8.11M.
- There are more short-term assets than short-term liabilities on the FULC balance sheet.
- FULC profit margin has gone up from -3,961.2% to -0.6% in the past year.
- FULC has a low debt to equity ratio of 0.06.
- Total FULC debt is lower than 5 years ago, relative to shareholder equity.
Failed Financial Due Diligence Checks:
- FULC earnings of -$510.00k is not enough to cover its interest payments.
Is FULC stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 4 Equities analysts who monitor FULC, the consensus analyst rating on Fulcrum Therapeutics is a Strong Buy
Please note that analyst ratings are not recommendations, nor are they financial advice.
You can dig deeper into what analysts are forecasting on the Fulcrum Therapeutics stock forecast page.
Metrics for Advanced FULC Traders
FULC Earnings
Last year, FULC revenue was $80.00M. Over the last 5 year, FULC's revenue has grown by 154.45% per year. This was faster than the Biotechnology industry average of 43.24%.
You can research FULC's earnings and revenue performance here.
Are FULC insiders buying or selling the stock?
Over the last year, executives and large shareholders at FULC have bought more shares than they have sold.
Greg Tourangeau, Principal Accounting Officer of FULC, was the latest FULC insider to sell. They sold $2,519.88 worth of FULC shares on May 8, 2025.
Research more about who owns FULC stock here.
Does FULC provide a stable income stream?
No, Fulcrum Therapeutics doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your FULC trade
You have two main order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly the best for newer investors. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a specific dollar amount, use a limit order.
Hit the Open Trade button and eToro will execute your order.
If you require additional help buying stocks on eToro, watch the helpful video below:
Step 6: Get updates on your FULC investment
Now that you own some FULC stock, you'll want to stay up-to-date on your new shares.
Put FULC on a watchlist to track the most important metrics related to your FULC stock.
FULC Feed
How to Buy Stock in Fulcrum Therapeutics
To summarize, here are the 6 steps to buy stock in Fulcrum Therapeutics:
- Decide where to buy Fulcrum Therapeutics stock
- Open a brokerage account
- Deposit funds into your investment account
- Research Fulcrum Therapeutics stock
- Execute your FULC trade
- Get updates on your FULC investment
If you need a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you would like to keep an eye on your new investment in Fulcrum Therapeutics, get started below.
Other "How To" Guides You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.